SCHEMBL6417119

SCHEMBL6417119

NN=C(c1cc(Cl)ccc1O)c1nc2nonc2nc1NCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB P07437 1/20 0.40
RXFP1 Q9HBX9 1/20 0.38
STAT6 P42226 2/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 3/20 0.37
KDM4E B2RXH2 2/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
APP P05067 2/20 0.37
MAPT P10636 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
DDX3X O00571 1/20 0.36
CDK9 P50750 1/20 0.36
IDO1 P14902 1/20 0.36
LMNA P02545 2/20 0.35
HTT P42858 2/20 0.35
MAT2A P31153 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6414661 0.88 MEN1 (0.37) RXFP1STAT6KDM4EGAAL3MBTL1
SCHEMBL6414671 0.88 MEN1 (0.37) RXFP1STAT6KDM4EGAAL3MBTL1
SCHEMBL6433414 0.86 EGFR (0.39) ALDH1A1HPGDKDM4EL3MBTL1APP
SCHEMBL6416311 0.85 TP53 (0.42) RXFP1HPGDPOLBMAPTMEN1
SCHEMBL6416319 0.85 TP53 (0.42) RXFP1HPGDPOLBMAPTMEN1
SCHEMBL6415738 0.84 EGFR (0.39) RXFP1STAT6KDM4EL3MBTL1MAPT
SCHEMBL6415718 0.84 EGFR (0.39) RXFP1STAT6KDM4EL3MBTL1MAPT
SCHEMBL6413651 0.81 KDM5B (0.42) ALDH1A1HPGDKDM4EPOLBGAA
SCHEMBL6413677 0.81 KDM5B (0.42) ALDH1A1HPGDKDM4EPOLBGAA
SCHEMBL6416987 0.80 EGFR (0.39) ALDH1A1APPMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 TUBB 2989/4885RXFP1 1728/4885STAT6 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.